ReNeuron’s announcement of early but exciting data on three patients in the clinical study of its human retinal progenitor cell (hRPC) product was well received. Although the patient numbers are small and the follow-up time points are short (two months and 18 days), the improvements in visual acuity are striking and may enable an earlier start to the pivotal programme.
22 Feb 2019
ReNeuron Group - Exciting positive data in retinitis pigmentosa (RP)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - Exciting positive data in retinitis pigmentosa (RP)
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
22 Feb 2019 -
Author:
Dr Andy Smith -
Pages:
3
ReNeuron’s announcement of early but exciting data on three patients in the clinical study of its human retinal progenitor cell (hRPC) product was well received. Although the patient numbers are small and the follow-up time points are short (two months and 18 days), the improvements in visual acuity are striking and may enable an earlier start to the pivotal programme.